open access

Vol 10, Supp. C (2014)
Case report
Published online: 2014-08-29
Get Citation

The treatment of patients with metastatic prostate cancer with performance status equal 2 according to the Eastern Cooperative Oncology Group with the use of abiraterone — case reports

Paweł Wiechno

open access

Vol 10, Supp. C (2014)
CASE REPORT
Published online: 2014-08-29

Abstract

Currently, metastatic prostate cancer should be considered as a chronic disease. Recent years have brought new opportunities in treatment of patients in the phase of the disease that is resistant to hormone therapy. The paper presents a description of the treatment of a patients with metastatic prostate cancer, with performance status equal 2, according to the Eastern Cooperative Oncology Group, with the use of abiraterone. That is a good illustration of the possibilities of multi-stage therapy of patients with castrate resistant prostate cancer.

Abstract

Currently, metastatic prostate cancer should be considered as a chronic disease. Recent years have brought new opportunities in treatment of patients in the phase of the disease that is resistant to hormone therapy. The paper presents a description of the treatment of a patients with metastatic prostate cancer, with performance status equal 2, according to the Eastern Cooperative Oncology Group, with the use of abiraterone. That is a good illustration of the possibilities of multi-stage therapy of patients with castrate resistant prostate cancer.

Get Citation

Keywords

castrate resistant prostate cancer, docetaxel, abiraterone

About this article
Title

The treatment of patients with metastatic prostate cancer with performance status equal 2 according to the Eastern Cooperative Oncology Group with the use of abiraterone — case reports

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. C (2014)

Article type

Case report

Pages

1-5

Published online

2014-08-29

Keywords

castrate resistant prostate cancer
docetaxel
abiraterone

Authors

Paweł Wiechno

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl